AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22926596 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 316
Study 22926596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study 16050407 — intervention group
Group type: EXPERIMENTAL
Intervention: Blockers of the renin-angiotensin system (RAS)
Number of subjects: 0
Study 16050407 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict control of blood pressure (PA)
Number of subjects: 0
Study 16050407 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of RAS blockers in presence of microalbuminuria
Number of subjects: 0
Study 12853792 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mmol (3%) ALA administered for 6 hours
Number of subjects: 18
Study 12853792 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mmol (0.2%) HAL administered for 4 hours
Number of subjects: 18
Study 12853792 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mmol HAL administered for 2 hours followed by 2 hours of resting time (2+2 hours concept)
Number of subjects: 18
Study 12853792 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of HAL
Number of subjects: 18
Study 12853792 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of ALA or HAL
Number of subjects: 18
Study 10217357 — intervention group
Group type: EXPERIMENTAL
Intervention: 85% concentrate of omega-3 fatty acids (Omacor)
Number of subjects: 40
Study 10217357 — intervention group
Group type: COMPARATOR
Intervention: Untreated normolipidemic subjects
Number of subjects: 40
Study 7573813 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified nasal lavage technique after unilateral antigen challenge
Number of subjects: 20
Study 2696390 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course therapeutic regimen consisting of isoniazid, rifampicin, and pyrazinamide for the first two months, followed by isoniazid and rifampicin for the next four months.
Number of subjects: 50
Study 2696390 — intervention group
Group type: COMPARATOR
Intervention: Classical therapy consisting of isoniazid and rifampicin for a nine-month period.
Number of subjects: 50
Study 851042 — intervention group
Group type: EXPERIMENTAL
Intervention: 47 mm² electrode
Number of subjects: 94
Study 851042 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mm² electrode
Number of subjects: 94
Study 851042 — intervention group
Group type: EXPERIMENTAL
Intervention: New large contact area-small active surface electrode
Number of subjects: 94
Study 851042 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulse duration of 2 msec
Number of subjects: 94
Study 12395952 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider advice to quit smoking
Number of subjects: 432
Study 12395952 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual Papanicolaou test in the prior 3 years
Number of subjects: 432
Study 12395952 — intervention group
Group type: EXPERIMENTAL
Intervention: Readiness to quit smoking
Number of subjects: 432
Study 12395952 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine dependence
Number of subjects: 432
Study 29722425 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green-based photodynamic therapy
Number of subjects: 21
Study 29722425 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green-based photodynamic therapy with 805-nm diode laser
Number of subjects: 21
Study 29722425 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green-based photodynamic therapy with 830-nm light-emitting diode
Number of subjects: 21
Study 29722425 — intervention group
Group type: COMPARATOR
Intervention: Methyl aminolevulinate-based photodynamic therapy
Number of subjects: 21
Study 26763947 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic leg-press training with moderate vibration (n=26)
Number of subjects: 55
Study 26763947 — intervention group
Group type: COMPARATOR
Intervention: Functional physiotherapy (n=29)
Number of subjects: 55
Study 24562088 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Feedback Awareness and Control Training (A-FACT)
Number of subjects: 40
Study 24562088 — intervention group
Group type: COMPARATOR
Intervention: Active placebo control condition
Number of subjects: 40
Study 22547331 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 64
Study 20299633 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of communication (QOC)
Number of subjects: 342
Study 18566974 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-6002 (istradefylline)
Number of subjects: 2
Study 18566974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold KW-6002
Number of subjects: 2
Study 18566974 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral doses of KW-6002 greater than 5 mg
Number of subjects: 2
Study 18566974 — intervention group
Group type: COMPARATOR
Intervention: MRS 1745 (A(2B) receptor selective antagonist)
Number of subjects: 2
Study 16227335 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. tramadol 100 mg
Number of subjects: 60
Study 16227335 — intervention group
Group type: COMPARATOR
Intervention: famotidine 20 mg
Number of subjects: 60
Study 11862087 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 100 mg orally, three times daily
Number of subjects: 40
Study 11862087 — intervention group
Group type: COMPARATOR
Intervention: Topical steroid, topical antibiotic, and artificial tears
Number of subjects: 40
Study 10549464 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: propofol 2 mg kg‐1 and remifentanil 2 micrograms kg‐1
Number of subjects: 40
Study 10549464 — intervention group
Group type: COMPARATOR
Intervention: Group 2: propofol 2 mg kg‐1, remifentanil 1 microgram kg‐1 and lignocaine 1 mg kg‐1
Number of subjects: 40
Study 10549464 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 7606988 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 micrograms twice a day
Number of subjects: 20
Study 7606988 — intervention group
Group type: COMPARATOR
Intervention: Albuterol, 400 micrograms four times a day
Number of subjects: 20
Study 2297260 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine added to cyclosporine, azathioprine, and prednisone
Number of subjects: 54
Study 2297260 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine, azathioprine, and prednisone (control group)
Number of subjects: 54
Study 348380 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticrynafen
Number of subjects: 28
Study 348380 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 28
Study 348380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31234865 — intervention group
Group type: EXPERIMENTAL
Intervention: Single low-dose primaquine added to artemether-lumefantrine treatment
Number of subjects: 166
Study 31234865 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine treatment without primaquine
Number of subjects: 166
Study 28070970 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower seed oil (SSO)
Number of subjects: 50
Study 28070970 — intervention group
Group type: COMPARATOR
Intervention: Baby lotion (L)
Number of subjects: 50
Study 28070970 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 50
Study 26254819 — intervention group
Group type: EXPERIMENTAL
Intervention: New lingually based triangular flap
Number of subjects: 22
Study 26254819 — intervention group
Group type: COMPARATOR
Intervention: Traditional triangular flap
Number of subjects: 22
Study 23126384 — intervention group
Group type: EXPERIMENTAL
Intervention: montelukast (5 or 10 mg, once daily)
Number of subjects: 62
Study 23126384 — intervention group
Group type: COMPARATOR
Intervention: salmeterol (50 μg, b.i.d.)
Number of subjects: 62
Study 21439514 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline monotherapy
Number of subjects: 127
Study 21439514 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin-aztreonam
Number of subjects: 127
Study 20077991 — intervention group
Group type: EXPERIMENTAL
Intervention: Res-Care Intervention (two-tiered motivational intervention)
Number of subjects: 0
Study 20077991 — intervention group
Group type: EXPERIMENTAL
Intervention: Future work recommendations
Number of subjects: 0
Study 16426100 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (340 mg, N = 44; 425 mg, N = 82)
Number of subjects: 190
Study 16426100 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 64)
Number of subjects: 190
Study 16426100 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 190
Study 14503435 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Therapy (CI therapy)
Number of subjects: 0
Study 14503435 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 0
Study 10919420 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedated patients (Study A)
Number of subjects: 220
Study 10919420 — intervention group
Group type: COMPARATOR
Intervention: Nonsedated patients (Study A)
Number of subjects: 220
Study 10919420 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (no supplementary oxygen, Study B)
Number of subjects: 220
Study 10919420 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (0 min pre-oxygenation, Study B)
Number of subjects: 220
Study 10919420 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (2 min pre-oxygenation, Study B)
Number of subjects: 220
Study 10919420 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (5 min pre-oxygenation, Study B)
Number of subjects: 220
Study 8724448 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.1 mg, 0.25 mg, 0.5 mg)
Number of subjects: 23
Study 8724448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 1314536 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-attenuated vaccine (28,000 pfu, 2800 pfu, or 280 pfu of Oka/Merck strain virus)
Number of subjects: 95
Study 1314536 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-inactivated vaccine (comparable antigen content to live vaccine)
Number of subjects: 95
Study 1314536 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose groups (greater than or equal to 7.1 antigen units)
Number of subjects: 95
Study 1314536 — intervention group
Group type: COMPARATOR
Intervention: Lowest dose (less than or equal to 0.71 antigen units)
Number of subjects: 95
Study 2864890 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol hydrochloride tablet formulation
Number of subjects: 11
Study 2864890 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol hydrochloride syrup formulation
Number of subjects: 11
Study 31826893 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone coaching (education session + 8 sessions over 12 weeks)
Number of subjects: 72
Study 31826893 — intervention group
Group type: COMPARATOR
Intervention: Control (education session only)
Number of subjects: 72
Study 29040663 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT and H-FABP measured at 0, 4, 6, and 24 hours post PCI
Number of subjects: 209
Study 29040663 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT and H-FABP at 4 hours post PCI
Number of subjects: 209
Study 29040663 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for major adverse clinical events (MACE) at 1 year
Number of subjects: 209
Study 29040663 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT and H-FABP
Number of subjects: 209
Study 27102843 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-field irradiation (EFI)
Number of subjects: 116
Study 27102843 — intervention group
Group type: COMPARATOR
Intervention: Pelvic only radiotherapy (PRT)
Number of subjects: 116
Study 24201305 — intervention group
Group type: EXPERIMENTAL
Intervention: FuFIRI
Number of subjects: 423
Study 24201305 — intervention group
Group type: EXPERIMENTAL
Intervention: mIROX
Number of subjects: 423
Study 22003819 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotripsy (PCNL)
Number of subjects: 64
Study 22003819 — intervention group
Group type: COMPARATOR
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 64
Study 20175876 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 2399
Study 20175876 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 2399
Study 20175876 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 2399
Study 18019664 — intervention group
Group type: EXPERIMENTAL
Intervention: Immodin (IM)
Number of subjects: 45
Study 18019664 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 45
Study 16145697 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized visual incentives (CVI)
Number of subjects: 47
Study 16145697 — intervention group
Group type: COMPARATOR
Intervention: Spirometry without CVI
Number of subjects: 47
Study 16145697 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry with CVI
Number of subjects: 47
Study 11876665 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape only (15 groups)
Number of subjects: 75
Study 11876665 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape plus skills instruction (18 groups)
Number of subjects: 75
Study 10541304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein restriction
Number of subjects: 0
Study 10541304 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary analyses of the MDRD Study
Number of subjects: 0
Study 8886347 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy + micronutrient supplementation
Number of subjects: 136
Study 8886347 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient alone
Number of subjects: 136
Study 8886347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 2062510 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg per day)
Number of subjects: 3711
Study 2062510 — intervention group
Group type: EXPERIMENTAL
Intervention: Early argon laser photocoagulation
Number of subjects: 3711
Study 2062510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3711
Study 2062510 — intervention group
Group type: COMPARATOR
Intervention: Deferral of photocoagulation
Number of subjects: 3711
Study 6129797 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen I (glutamate 1.5 mmol/kg/day and aspartate 1.0 mmol/kg/day)
Number of subjects: 8
Study 6129797 — intervention group
Group type: COMPARATOR
Intervention: Regimen II (no glutamate and aspartate)
Number of subjects: 8
Study 6129797 — intervention group
Group type: COMPARATOR
Intervention: Normal, orally fed premature infants
Number of subjects: 8
Study 6129797 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen I and II
Number of subjects: 8
Study 31031463 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (PQ)
Number of subjects: 53
Study 28967485 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks
Number of subjects: 370
Study 26311100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular dexmedetomidine (2 μg/kg body weight) and ropivacaine (18 mL)
Number of subjects: 60
Study 26311100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular dexmedetomidine (1 μg/kg body weight) and ropivacaine (18 mL)
Number of subjects: 60
Study 26311100 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular ropivacaine (20 mL)
Number of subjects: 60
Study 23567483 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 μg/kg/min remifentanil infusion (Group R1)
Number of subjects: 70
Study 23567483 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 μg/kg/min remifentanil infusion (Group R2)
Number of subjects: 70
Study 20518009 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic total occlusion (CTO) group
Number of subjects: 1071
Study 18454862 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut supplement (75 g/d)
Number of subjects: 21
Study 16567267 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose thiamine (250 mg/day) and pyridoxine (200 mg/day)
Number of subjects: 50
Study 16567267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15050679 — intervention group
Group type: EXPERIMENTAL
Intervention: Asked for a collateral and provided one
Number of subjects: 0
Study 15050679 — intervention group
Group type: COMPARATOR
Intervention: Asked for a collateral but did not provide one
Number of subjects: 0
Study 11063954 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of > or = 20 cigarettes per day
Number of subjects: 21068
Study 11063954 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of <20 cigarettes per day
Number of subjects: 21068
Study 11063954 — intervention group
Group type: EXPERIMENTAL
Intervention: Past smokers
Number of subjects: 21068
Study 11063954 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of > or = 20 cigarettes per day (after multivariate adjustment)
Number of subjects: 21068
Study 11063954 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of <20 cigarettes per day (after multivariate adjustment)
Number of subjects: 21068
Study 11063954 — intervention group
Group type: EXPERIMENTAL
Intervention: Past smokers (after multivariate adjustment)
Number of subjects: 21068
Study 11063954 — intervention group
Group type: EXPERIMENTAL
Intervention: Total pack‐years of cigarette smoking
Number of subjects: 21068
Study 9057634 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive transfusion (group 1, 110 patients)
Number of subjects: 364
Study 9057634 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative transfusion (group 2, 120 patients)
Number of subjects: 364
Study 9057634 — intervention group
Group type: COMPARATOR
Intervention: Nontransfusion (group 3, 37 patients)
Number of subjects: 364
Study 9057634 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrandomized transfusion (group 4, 97 patients)
Number of subjects: 364
Study 9057634 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 364
Study 9057634 — intervention group
Group type: EXPERIMENTAL
Intervention: Open cholecystectomy
Number of subjects: 364
Study 8334805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer repeatability
Number of subjects: 30
Study 8334805 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-observer repeatability
Number of subjects: 30
Study 8334805 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term repeatability
Number of subjects: 30
Study 8334805 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous evolution over 8 hours
Number of subjects: 30
Study 3094617 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based TPN regimen (Intralipid providing 50% of calorific requirement)
Number of subjects: 23
Study 3094617 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-based TPN regimen (control)
Number of subjects: 23
Study 3189208 — intervention group
Group type: EXPERIMENTAL
Intervention: Village health program
Number of subjects: 11000
Study 3189208 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie snacks
Number of subjects: 11000
Study 3189208 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-mineral supplements
Number of subjects: 11000
Study 3189208 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 11000
Study 31664766 — intervention group
Group type: EXPERIMENTAL
Intervention: BOS161721 (1-240 mg, intravenous and subcutaneous doses)
Number of subjects: 0
Study 31664766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31664766 — intervention group
Group type: EXPERIMENTAL
Intervention: BOS161721 (subcutaneous)
Number of subjects: 0
Study 31664766 — intervention group
Group type: EXPERIMENTAL
Intervention: BOS161721
Number of subjects: 0
Study 30475457 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation System (BAS)
Number of subjects: 53
Study 30475457 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Inhibition System (BIS)
Number of subjects: 53
Study 28477860 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 13400
Study 28477860 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 13400
Study 28477860 — intervention group
Group type: COMPARATOR
Intervention: Normal weight group (reference)
Number of subjects: 13400
Study 28477860 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight group
Number of subjects: 13400
Study 25142280 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Number of subjects: 130
Study 25142280 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (grade 5 strength)
Number of subjects: 130
Study 23906160 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical risk variables and PlGF measurement
Number of subjects: 3529
Study 23906160 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical risk variables
Number of subjects: 3529
Study 23906160 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=188)
Number of subjects: 3529
Study 20191568 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-joint count (JC28)
Number of subjects: 182
Study 20191568 — intervention group
Group type: EXPERIMENTAL
Intervention: 32-joint count (JC32)
Number of subjects: 182
Study 20191568 — intervention group
Group type: EXPERIMENTAL
Intervention: 36-joint count (JC36)
Number of subjects: 182
Study 20191568 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression for ACR20 response
Number of subjects: 182
Study 20191568 — intervention group
Group type: EXPERIMENTAL
Intervention: American College of Rheumatology (ACR) responses
Number of subjects: 182
Study 17940553 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Number of subjects: 0
Study 17940553 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 0
Study 16970214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/d) added to ongoing statin therapy for 6 weeks
Number of subjects: 3030
Study 16970214 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to ongoing statin therapy for 6 weeks
Number of subjects: 3030
Study 15595305 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% VO2(peak)
Number of subjects: 55
Study 15595305 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% VO2(peak)
Number of subjects: 55
Study 15595305 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55